Daily Low-Dose Ketamine: Why Repetition May Matter More Than Intensity - Eiad Asbahi
Release Date: 10/20/2026
The Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Eiad Asbahi, founder of , a patient care coordination platform that connects people with licensed providers and pharmacies for low-dose ketamine care. Eiad spent 17 years running a hedge fund and reached the kind of success he had always dreamed about. Then his largest investment collapsed and his marriage ended, and he was forced to look inward. This epsiode is sponsored by Eiad Asbahi. Eiad describes the moment he realized he was the common denominator in his own failures. He talks about the core belief underneath it...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Mira Funk, LCSW, a Harvard-educated psychotherapist and the founder of , a private practice built around 5-MeO-DMT, N,N-DMT, and salvia divinorum. This episode is sponsored by Mira Funk. Mira traces her path from fourteen years of Zen meditation into psychedelic work, and explains how a severe reaction to a common nootropic supplement unexpectedly reoriented her entire practice toward presence rather than dramatic, otherworldly trips. She and Paul go deep on the extended-release routes she has pioneered, including...
info_outlineThe Psychedelic Podcast
Paul talks with biohacking pioneer Dave Asprey about medicalization, microdosing, consciousness, and Dave's new BEYOND Wonderland psychedelics conference in Austin. In this bonus episode, Paul welcomes back Dave Asprey, founder of Bulletproof Coffee and creator of the biohacking movement, to talk about BEYOND Wonderland, the psychedelics conference Dave has revamped for October 12-14 in Austin. They also get into medicalization, the CIA's documented role in psychedelic history, what responsible microdosing regulation could look like, and why Dave is as focused on unlocking latent human ability...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with computer scientist, climate investor, and Nexus author Ramez Naam about psychedelics, AI, neurotechnology, and cognitive liberty. Find full show notes and links here: Ramez shares how psychedelic experiences sparked his interest in neuroscience, inspired his books, and helped redirect his work toward climate and clean energy. He and Paul explore what brain-computer interfaces can do today, the future of psychedelic mental healthcare, and how to protect freedom of thought as AI becomes a more personal tool. Ramez Naam is a...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with therapist and InnerEthics® founder Kylea Taylor about why responsible psychedelic therapy requires more than good intentions. Find full show notes and links here: Kylea explains why non-ordinary states can amplify intimacy, vulnerability, countertransference, and practitioner blind spots. She presents ethics as an ongoing practice of self-inquiry, restraint, and right relationship rather than a set of rules consulted only after something goes wrong. Paul and Kylea also examine personal experience as preparation for...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Paije Alexandra West, founder of , about iboga, ibogaine, and Bwiti initiation. Drawing on Paul’s recent retreat experience at ETÉREO in Baja, they examine what can be lost when iboga is reduced to a clinical alkaloid and how traditional ceremony can coexist with rigorous medical screening. Paije explains the differences between iboga root bark and total alkaloid extract, the role of Bwiti music, and why discomfort, community, and long-term integration are central to working responsibly with this demanding medicine....
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with psychiatrist and TaperClinic founder Dr. Josef Witt-Doerring about antidepressant withdrawal, psychiatric deprescribing, and psychedelic readiness. Find full show notes and links here: Josef explains what he learned reviewing drug safety at the FDA, why withdrawal can be mistaken for relapse, and how tapering often becomes more difficult at lower doses. They also explore the lifestyle foundations of mental health, benzodiazepine withdrawal, and why psychedelic clinics may need far more sophisticated support as increasingly...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with investigative journalist Robert Whitaker about the evidence behind psychiatric prescribing, SSRI withdrawal, and what psychedelic medicine can learn from that history. Find full show notes and links here: Whitaker revisits the chemical imbalance theory, long-term antidepressant outcomes, and how psychiatric drugs evolved from short-term interventions toward chronic use. He also explores the social and environmental dimensions of mental health before turning to psychedelic medicine and the risks of recreating a...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Dr. Remi Drozd back to explore ketamine, SSRIs, and the changing landscape of psychedelic mental health care. Find full show notes and links here: Since Remi first appeared on the podcast in Episode 182, Lucid Therapeutics has grown from a small ketamine practice into a ten-room interventional mental health clinic offering ketamine treatments, Spravato, TMS, therapy, integration support, and other approaches. Paul and Remi examine one of the less-discussed challenges facing psychedelic medicine: many prospective patients are...
info_outlineThe Psychedelic Podcast
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Dr. Richard Louis Miller about what psychedelic medicine must get right as it moves toward broader acceptance. Richard explains why transparent reporting of adverse effects is essential to informed choice, where research still leaves important gaps, and how commercialization could shape access and treatment. They examine 5-MeO-DMT, group therapy, and the limits of one-to-one care. Richard also shares his approach to aging through exercise, real food, rest, and human connection. Dr. Richard Louis Miller is a clinical...
info_outlineIn this episode of The Psychedelic Podcast, Paul F. Austin sits down with Eiad Asbahi, founder of Mindscape, a patient care coordination platform that connects people with licensed providers and pharmacies for low-dose ketamine care. Eiad spent 17 years running a hedge fund and reached the kind of success he had always dreamed about. Then his largest investment collapsed and his marriage ended, and he was forced to look inward.
This epsiode is sponsored by Eiad Asbahi.
Eiad describes the moment he realized he was the common denominator in his own failures. He talks about the core belief underneath it all, that he was "defective," and how Internal Family Systems therapy showed him there are no bad parts. He explains how building inner safety changed the way he parents his daughter, and why he uses ketamine to reconnect rather than to escape. Paul and Eiad also discuss the thinking behind Mindscape's daily low-dose model and the case for repetition over peak experiences. The conversation ends with a candid disagreement about dependence, personal agency, clinical oversight, and what responsible access to ketamine should look like.
Eiad Asbahi is a founder and father. He spent 17 years running a hedge fund and reached the highest levels of professional success before a long professional collapse. Around the same time, a divorce sent him inward. He wanted to model a secure relationship for his daughter, so he began Internal Family Systems therapy and spent the next five years rebuilding his relationship with himself.
Eiad founded Mindscape to make the kind of guided, medically supervised care that changed his life easier to find and navigate. Mindscape is a patient care coordination platform that connects people with independently licensed providers and pharmacies, and its approach is built on repetition over intensity. Today his work centers on what comes after healing: deliberately rebuilding identity, motivation, and meaning.
Highlights:
- From hedge fund highs to a five-year professional collapse
- Realizing he was the common denominator in his failures
- The core belief beneath it all: feeling defective
- Internal Family Systems and the idea that there are no bad parts
- How repeated inner work builds inner safety
- Becoming the protector for his daughter that he never had
- How Mindscape's stripped-down model differs from other ketamine platforms
- Daily low-dose ketamine: repetition over intensity, connection over escape
- Eiad's self-care practices: movement, music, and red light
- Dependence, agency, and accountability: where Paul and Eiad disagree
Episode Links:
- Mindscape: https://themindscape.com/
- Mindscape on Instagram: https://www.instagram.com/themindscape.official
- Eiad on Instagram: https://www.instagram.com/eiadasbahi